莫西沙星序贯治疗卫生保健相关性肺炎疗效观察

目的: 观察莫西沙星序贯治疗卫生保健相关性肺炎(healthycare associated pneumonia，HCAP)的临床疗效。方法： 选取HCAP患者62例，随机分成2组，治疗组31例，静滴莫西沙星0.4 g，1次/d，症状改善后加口服序贯治疗，疗程8~12 d；对照组31例，静滴头孢替安2.0 g/次，2次/d，疗程10~14 d；比较两组治疗效果。结果： 治疗组和对照组临床有效率分别为93.5%和71.0%，细菌清除率分别为94.7%和61.1%，两组间差异均有统计学意义(P均<0.05)；治疗组疗程明显短于对照组(P<0.01)。结论： 莫西沙星序贯治疗HCAP有效，细菌清除率高，有较高的临床价值。

Clinical observation on moxifloxacin sequential therapy for healthcare-associated pneumonia

Objective: To evaluate the clinical efficacy of moxifloxacin sequential therapy on patients with healthcare associated pneumonia(HCAP). Methods: Sixty-two patients with HCAP hospitalized from January 2010 to January 2013 in the emergency ward of Shanghai Gongli Hospital were randomly divided into two groups, the treatment group(n=31) was administrated 0.4 g moxifloxacin intravenously, once a day, took the same medicine orally when the symptoms were improved, with total treatment course of 8~12 d; and the control group(n=31) was administrated 2.0 g cefotiam intravenously, twice a day, with total treatment course of 10~14 d. The efficacy of two groups was compared. Results: The clinical curative effect rates of moxifloxacin and cefotiam were 93.5% and 71.0%, the bacterial clearance rates were 94.7% and 61.1%, respectively; moxifloxacin was better than cefotiam in clinical curative effect(P<0.05). Conclusion: The anti-infection function of moxifloxacin sequential therapy was effective, meanwhile, with high bacterial clearance rate and clinical value.